The $960.4 million initial public offering (IPO) of Manipal Health Enterprises was fully subscribed on its final day of bidding, propelled almost entirely by aggressive institutional demand that offset muted enthusiasm from retail investors. Exchange data showed the issue received bids for 229 million shares against 90.09 million shares on offer, led by Qualified Institutional Buyers (QIBs) who subscribed 4.3 times their allocated portion. Conversely, retail investors booked just 62 percent of their quota, while non-institutional investors placed bids for only 29 percent. India’s second-biggest IPO of the year—comprising an ₹8,000 crore fresh issue and a ₹1,275 crore offer for sale—saw retail participation constrained by valuation concerns. Valued at 84.65 times its FY26 earnings at the upper price band of ₹590 per share, the healthcare major trades at a noticeable premium over listed peers like Apollo Hospitals and Max Healthcare, leading market analysts to anticipate a subdued stock exchange listing on August 5.
Despite retail hesitation, institutional backing remains anchored by the hospital chain’s market position as India’s largest multispecialty healthcare network by bed capacity, operating over 13,000 beds across 49 hospitals. Ahead of the public offer, the Temasek-backed company raised ₹4,167 crore from anchor investors, including the Abu Dhabi Investment Authority and Allianz Global Investors. Proceeds from the fresh issue will primarily be deployed to reduce existing debt and acquire a minority stake in its subsidiary, Sahyadri Hospitals. While retail sentiment reflected caution over fully priced growth prospects, strong institutional demand underscores long-term investor confidence in the hospital operator’s earnings visibility and national footprint expansion.
